Postreperfusion syndrome, hyperkalemia and machine perfusion in liver transplantation by Patrono, Damiano & Romagnoli, Renato
© Translational Gastroenterology and Hepatology. All rights reserved. Transl Gastroenterol Hepatol 2019;4:68 | http://dx.doi.org/10.21037/tgh.2019.08.12
Postreperfusion syndrome in liver transplantation
In liver transplantation (LT), postreperfusion syndrome 
(PRS) is represented by a series of transient hemodynamic 
alterations occurring after graft reperfusion into the 
recipient, including bradycardia, dysrhythmia, decreased 
systemic vascular resistance and mean arterial pressure 
(MAP), and increased pulmonary artery pressure, pulmonary 
artery wedge pressure and central venous pressure. It can be 
associated with acute acidosis, hypothermia, hyperkalemia 
and hyperfibrinolysis. It was first defined by Aggarwal 
et al. (1) as a decrease in MAP ≥30% from baseline for at 
least one minute within 5 minutes from graft reperfusion, 
and further classified by Hilmi et al. (2) into mild PRS 
(i.e., a <5 minutes-long decrease in blood pressure and/
or heart rate <30% of the anhepatic levels, responsive to 
calcium chloride and/or epinephrine intravenous boluses, 
without continuous vasopressors infusion requirement) 
and significant PRS (characterized by severe hemodynamic 
instability with hypotension [>30% of the anhepatic level], 
asystole, hemodynamically significant arrhythmias, and 
including also patients with prolonged and/or recurrent 
fibrinolysis). In severe cases, PRS can degenerate to cardiac 
arrest and on-table death after graft reperfusion. 
Pathogenesis of PRS is complex and incompletely 
understood. The cause of PRS is generally attributed to 
the interplay between metabolic acidosis, hyperkalemia, 
hypocalcemia, hypothermia, air embolism, and the 
hemodynamic effects of vasoactive substances released 
at the time of graft reperfusion. After graft reperfusion, 
many inflammatory cytokines (TNF-α, IL-1, IL-2, IL-8) 
are released into systemic circulation by the grafted liver. 
Others, like kallikrein, bradykinin, chemokines and activated 
complement factors are produced by the recipient in response 
to graft reperfusion. The importance of each of them in 
determining PRS, however, has not been elucidated so far (3).
Incidence of PRS varies widely across different studies, 
ranging from 10% to 58%, and this is at least partially due 
to some heterogeneity in PRS definition (4-11). Incidence 
of PRS does not appear to have decreased in recent years; 
its occurrence is clinically relevant as it has been associated 
with the onset of postoperative acute kidney injury (AKI) 
(12,13), early allograft dysfunction, and, although less 
frequently, reduced graft and patient survival (8). 
Risk factors for PRS include donor [age, macrosteatosis, 
donation after circulatory death (DCD)] and recipient 
(severity of liver disease, previous myocardial dysfunction) 
features, and factors related to transplant operation 
(duration of cold and warm ischemia time, blood products 
transfusion and calcium requirements, surgical technique, 
hyperkalemia and hypothermia after graft reperfusion) 
(4,5,7,10-12,14). The association between factors like 
donor age, graft macrosteatosis, donation after cardiac 
death and duration of cold ischemia time suggests that 
ischemia-reperfusion injury and onset of PRS are closely 
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interlinked. In the study by Croome et al. (4), incidence 
of PRS and on-table cardiac arrest was higher in patients 
receiving grafts with moderate (30–60%) macrosteatosis, as 
compared to patients transplanted using grafts with mild or 
no steatosis. Pan et al. (7) observed that matched recipients 
of grafts from DCD donors, despite having comparable 
1-year patient and graft survival rates, had increased rates 
of PRS (25.7% versus 12.3%) and hyperkalemia (33.8% 
versus 18.9%) as compared to recipients of grafts from 
brain-dead donors (DBD). The detrimental effects of the 
combination of macrosteatosis and DCD was shown by 
Zhang et al. (10), who observed higher rates of PRS and 
postreperfusion hyperkalemia in recipients of DCD grafts 
with ≥20% macrosteatosis. Kalisvaart et al. (12) demonstrated 
the association between PRS, a more severe ischemia-
reperfusion injury, as reflected by higher transaminases peak, 
and subsequent AKI. These observations are also in keeping 
with the role of cold ischemia time as a risk factor for PRS, 
as prolonged preservation causes progressive adenosine 
triphosphate (ATP) depletion and aggravates ischemia-
reperfusion injury (11). Thus, PRS can be interpreted as 
an early hallmark of severe ischemia-reperfusion injury, 
explaining its association with AKI and patient outcome.
Hyperkalemia iN PRS: where does the potassium 
come from?
The possibility of PRS and hyperkalemia is well known to 
anesthetists involved in LT programs. Usually, during the 
anhepatic phase before graft reperfusion efforts are made 
to keep potassium levels on the low side, and all means to 
reduce potassium levels, like sodium bicarbonate, glucose, 
insulin and calcium infusions, are set ready for use. After 
graft reperfusion, hyperkalemia can result from acute 
metabolic acidosis, causing and extracellular potassium 
ions shift in exchange of H+, from exogenous potassium 
administration associated with red blood cells transfusion, 
and from the flush of potassium-rich preservation solution 
(like University of Wisconsin solution) from the graft 
into recipient circulation. This last has been particularly 
emphasized, and some studies have detected an association 
between potassium concentration of effluent flush fluid and 
severe PRS (9). However, two facts should be acknowledged. 
First, liver graft is usually flushed before implantation, 
either ex-situ with chilled 5% albumin or saline, or in-
situ with recipient blood. This practice, which reduces the 
amount of potassium released by liver graft at reperfusion, 
has reduced but not eliminated the incidence of PRS. 
Second, PRS can present when other preservation solutions 
with lower potassium concentration are used (Table 1). 
Thus, it appears that potassium contained in preservation 
solution is only partially responsible for postreperfusion 
recipient hyperkalemia. 
Intracellular potassium concentration is 140 to 
150 mEq/L, and is maintained by the balance between 
uphill cellular potassium uptake by the activity of sodium–
potassium ATPase, and passive potassium efflux (so-
called leak rate) (15). This process requires an intact and 
functioning cell membrane to actively pump potassium into 
the cell and limit leak rate. Cold preservation progressively 
determines cell membrane dysfunction and increased 
permeability (16) and can therefore reduce sodium–
potassium ATPase activity and increase passive potassium 
efflux, causing significant release of potassium from the 
intracellular space. As we would expect that to happen 
more significantly in more severely damaged liver, recipient 
hyperkalemia could be interpreted as a further sign of severe 
ischemia-reperfusion injury. This would provide a rationale 
to the association between potassium concentration of 
effluent flush fluid and severity of PRS, and also explain 
why different potassium concentrations can be measured 
on graft effluent flush fluid, despite the same preservation 
solution has been used. 
Impact of machine perfusion on PRS 
Since the advent of modern machine perfusion techniques, 
including normothermic machine perfusion (NMP), 
hypothermic oxygenated machine perfusion (HOPE) and 
their variants, a reduction in the incidence of PRS has 
been a common finding. Angelico et al. (17) compared 
intraoperative hemodynamics of 6 patients receiving 
grafts treated with NMP with 12 matched controls 
preserved by static cold storage (SCS). Although NMP 
did not significantly reduce raw incidence of PRS (0% 
versus 16.7%; P=0.53), it was associated with higher MAP 
90 minutes after graft reperfusion and lower norepinephrine 
requirement 5, 30 and 60 minutes after graft reperfusion. 
Furthermore, patients in the SCS group experienced 
a significant MAP drop 5 minutes postreperfusion, 
followed by a slow recovery to prereperfusion values after 
30 minutes, whereas patients in the NMP group had stable 
MAP as compared to the anhepatic phase. In the first 
multicenter randomized trial comparing NMP versus SCS, 
Nasralla et al. (18) observed, along with a 50% reduction of 
ischemia-reperfusion injury in the NMP group (AST peak: 
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Table 1 Composition of most common preservation solutions for liver transplantation
Solution component or characteristic Blood UW HTK IGL-1 SCOT 15 Celsior
Sodium ion (mmol/L) 140 30 15 120 118 100
Potassium ion (mmol/L) 5 125 9 25 5 15
Magnesium ion (mmol/L) 0.8 5 4 5 1.2 13
Calcium ion (mmol/L) 2.5 0.015 1.75 0.25
Chloride ion (mmol/L) 104
Sulphate ion (mmol/L) 1.4 5
Phosphate (mmol/L) 3.2 25
Bicarbonate (mmol/L) 25 25
Glucose (mmol/L) 7 11
Raffinose (mmol/L) 30 30
Lactobionate (mmol/L) 100 100 80
Adenosine (mmol/L) 5 5
Histidine (mmol/L) 180 30
Histidine · HCI · H2O (mmol/L) 18
Potassium hydrogen 2-ketoglutarate (mmol/L) 1
Mannitol (mmol/L) 30 60
Glutathione (mmol/L) 4 3 3
Allopurinol (mmol/L) 1 1
Tryptophan (mmol/L) 2
HES (g/L) 50
PEG 20KDa (g/L) 15
PEG 35KDa (g/L) 1
pH 7.4 7.3 7.4 7.4 7.3 7.4
Viscosity (centistokes) 1.6 2.4 1.8 1.28 1.6 1.15
Osmolarity (mOsm) 308 320 310 290 320 320
UW, University of Wisconsin; HTK, Histidine-Tryptophan-Ketoglutarate; IGL-1, Institut George Lopez-1; SCOT 15, Solution pour la 
Conservations des Organes pour la Transplantation-15; HES, hydroxyethyl starch; PEG, polyethylene glycol.
488 IU/L versus 965 IU/L; P<0.001), also a significant 
reduction of PRS rate (12.4% versus 33%; P<0.001). The 
only report of a possible detrimental effect of NMP on PRS 
was that by Watson et al. (19) from Cambridge. Authors 
reported 12 cases of LT using declined marginal liver grafts 
after NMP, among which the first 6 were performed with high 
mean arterial perfusate pO2 (621–671 mmHg). In this group, 
5 patients experienced PRS and 4 had persistent refractory 
vasoplegia after graft reperfusion, which was referred to high 
reactive oxygen and nitrogen species production during NMP 
due to perfusate hyperoxygenation. No case of PRS was 
observed in the subsequent 6 cases, performed using lower 
perfusate oxygen tensions (~150 mmHg). 
In our experience of hypothermic oxygenated machine 
perfusion, which has now reached 60 cases, onset of PRS 
has been anecdotal after HOPE treatment (20,21). In a 
matched patient cohort, incidence of PRS was reduced in 
HOPE group (4% versus 20%; P=0.13), a finding that was 
confirmed as significant by Bayesian model averaging. 
From a mechanistic standpoint, it is l ikely that 
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mitigation of ischemia-reperfusion injury and wash out 
of inflammatory cytokines have a prominent role in 
determining the reduction of PRS observed after machine 
perfusion. 
Recently, a paper by Burlage et al. (22) from University 
Medical Center Groningen, the Netherlands, shed new 
light on the relationship between machine perfusion, PRS 
and hyperkalemia. This paper, which analyzes sodium and 
potassium shifts in liver grafts during hypothermic machine 
perfusion and subsequent warm reperfusion, was prompted 
by a previous study from the same group in which, in 
contrast to what is normally observed at graft reperfusion 
after SCS, 3 out of 10 LT recipients whose grafts had been 
treated with HOPE experienced hypokalemia, instead of 
acute hyperkalemia (23). Briefly, Burlage and colleagues 
measured sodium and potassium concentrations in the 
perfusate during 2 hours of dual HOPE (DHOPE, i.e., 
HOPE performed by simultaneous perfusion of both portal 
vein and hepatic artery) and in the perfusate of subsequent 
NMP (n=6, preclinical study) or recipient blood (n=10, 
clinical study), calculating cation shifts during DHOPE, 
NMP and reperfusion into recipient. The control group 
was represented by 9 grafts undergoing NMP straight 
after SCS and by 9 matched patients transplanted with 
grafts preserved by conventional SCS in the preclinical and 
clinical study, respectively. In the preclinical study, cation 
shifts were correlated with markers of liver viability during 
NMP, including ATP cellular content, perfusate ALT and 
lactate levels. In the clinical study, the same shifts were 
correlated with markers of ischemia-reperfusion injury 
(ALT peak and postoperative day 1 prothrombin time) 
and with hemodynamic changes in the recipient at graft 
reperfusion (MAP and norepinephrine requirements). In 
both the preclinical and clinical study, Authors observed 
a potassium release in perfusate (17±2 and 34±6 mmol, 
respectively) and a sodium uptake (25±9 and 24±14 mmol, 
respectively)  during 2 hours of  DHOPE. During 
subsequent NMP, these shifts inverted in DHOPE treated 
livers, who exhibited active potassium uptake (19±3 mmol) 
and sodium release (7±3 mmol). In contrast, SCS-preserved 
liver released potassium and absorbed sodium during 
NMP. In the preclinical study, high potassium perfusate 
levels during NMP positively correlated with low cellular 
ATP content, peak ALT and lactate perfusate levels. In the 
clinical study, blood potassium levels decreased from 4.7±0.2 
to 3.9±0.3 mmol/L after DHOPE, whereas they increased 
from 4.4±0.1 to 5.0±0.4 mmol/L in recipients of SCS-
preserved livers. Increased potassium levels after portal 
reperfusion correlated with higher post-LT ALT peak and 
norepinephrine requirements. 
These results are extremely interesting. It is likely that 
sodium-potassium ATPase dysfunction caused potassium 
leakage and sodium uptake during DHOPE, which is 
in keeping with mild edema and weight gain that are 
commonly observed after HOPE. Upon warm reperfusion, 
both in the NMP and in-vivo setting, potassium uptake and 
sodium release by the reperfused liver could be result from 
preserved cellular membrane integrity and quicker recovery 
of sodium-potassium ATPase function induced by DHOPE, 
as opposed to what was observed in livers preserved by SCS. 
This observation was particularly convincing in the NMP 
setting, which is a closed circuit allowing avoiding many 
confounding factors of the in-vivo setting. To this regard, it 
would have been interesting to have data on potassium level 
on liver flush fluid obtained before NMP and in-vivo graft 
reperfusion for both DHOPE and SCS-preserved livers. 
It is not surprising that, in the preclinical study, lower 
cellular ATP levels correlated with higher ALT and 
lactate perfusate levels and higher potassium levels upon 
warm reperfusion, as these can all be considered markers 
of a more severe ischemia-reperfusion injury. Similarly, 
the association between higher potassium level upon 
in-vivo graft reperfusion and post-LT ALT peak and 
norepinephrine requirements go in the same direction. 
Overall, the article from the Groningen group is a further 
proof of the association between ischemia-reperfusion 
injury, PRS and acute hyperkalemia and provides a new 
insight on the mechanisms of graft reconditioning and 
protection during HOPE. PRS and acute hyperkalemia are 
signs of a more severe graft damage during preservation. 
Enhanced graft preservation is associated with improved 
hemodynamic stability upon graft reperfusion and, in some 
cases, with recipient hypokalemia. 
In the setting of NMP, it is likely that enhanced graft 
and cellular membrane integrity preservation and ATP 
restoration are also key determinants of reduced PRS rate 
and improved hemodynamic stability (17,18). A study 
evaluating sodium and potassium shift during NMP and 
subsequent in-vivo reperfusion would be particularly 
interesting. 
Clinical implications and future research 
directions
The results of Burlage et al. paper have clear clinical 
implications for anesthesiologic patient management during 
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LT. In recipient of HOPE-treated grafts, usual interventions 
to lower potassium levels could even be harmful and 
result in acute hypokalemia upon graft reperfusion. More 
“permissive” potassium levels could therefore be accepted 
before graft reperfusion. 
From another standpoint, these results could move the 
discussion about the indications for machine perfusion 
from a donor-oriented to a recipient-oriented approach. 
As machine perfusion technology comes to a significant 
cost, many efforts are being made to identify the settings 
in which it conveys a significant advantage over SCS. So 
far, these efforts have been focused on donor features. 
For instance, there is evidence that HOPE is superior to 
SCS in the setting of DCD LT and graft steatosis (24,25). 
However, indications for machine perfusion should take 
into account also recipient features. As suggested by 
Burlage and colleagues (22), DHOPE treatment could 
be particularly indicated in patients with pre-LT renal 
function impairment, as these patients are at increased 
risk of AKI, which is in turn strongly associated with PRS. 
Interestingly, in our experience improved postoperative 
renal function was the main benefit associated with HOPE 
treatment (21). As for patients at increased risk of AKI, 
HOPE could be considered in patients with particularly 
severe liver disease, with pre-LT myocardial dysfunction 
or when a difficult hepatectomy is foreseen, as these are all 
risk factors for PRS.
Machine perfusion could also serve as a platform to treat 
liver graft in an extra-corporeal setting. With regards to 
PRS, it would be interesting to evaluate the impact of a 
cytokine filter in parallel to the machine perfusion circuit 
to decrease the release of inflammatory cytokines at graft 
reperfusion. 
In conclusion, sodium and potassium shifts during 
DHOPE and warm reperfusion provide further evidence 
to the concept that PRS and acute hyperkalemia are early 
signs of severe ischemia-reperfusion injury, which can 
be mitigated by dynamic preservation techniques. The 
indications for machine perfusion use could be extended 
in LT candidates at increased risk of PRS. Future studies 
evaluating the impact of machine perfusion on PRS should 
ideally include measurements of cations and cytokines levels 





Conflicts of Interest: The authors have no conflicts of interest 
to declare.
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved.  
References
1. Aggarwal S, Kang Y, Freeman JA, et al. Postreperfusion 
syndrome: cardiovascular collapse following hepatic 
reperfusion during liver transplantation. Transplant Proc 
1987;19:54-5.
2. Hilmi I, Horton CN, Planinsic RM, et al. The impact of 
postreperfusion syndrome on short-term patient and liver 
allograft outcome in patients undergoing orthotopic liver 
transplantation. Liver Transpl 2008;14:504-8.
3. Jeong SM. Postreperfusion syndrome during liver 
transplantation. Korean J Anesthesiol 2015;68:527-39.
4. Croome KP, Lee DD, Croome S, et al. The impact of 
postreperfusion syndrome during liver transplantation 
using livers with significant macrosteatosis. Am J 
Transplant 2019;19:2550-9.
5. Fukazawa K, Yamada Y, Gologorsky E, et al. 
Hemodynamic recovery following postreperfusion 
syndrome in liver transplantation. J Cardiothorac Vasc 
Anesth 2014;28:994-1002.
6. Lee J, Yoo YJ, Lee JM, et al. Sevoflurane Versus Desflurane 
on the Incidence of Postreperfusion Syndrome During 
Living Donor Liver Transplantation: A Randomized 
Controlled Trial. Transplantation 2016;100:600-6.
7. Pan X, Apinyachon W, Xia W, et al. Perioperative 
complications in liver transplantation using donation after 
cardiac death grafts: a propensity-matched study. Liver 
Transpl 2014;20:823-30.
8. Siniscalchi A, Gamberini L, Bardi T, et al. Post-reperfusion 
syndrome during orthotopic liver transplantation, which 
definition best predicts postoperative graft failure and 
recipient mortality? J Crit Care 2017;41:156-60.
9. Zhang L, Tian M, Sun L, et al. Association Between 
Flushed Fluid Potassium Concentration and Severe 
Postreperfusion Syndrome in Deceased Donor Liver 
Transplantation. Med Sci Monit 2017;23:5158-67.
10. Zhang WJ, Xia WL, Pan HY, et al. Postreperfusion 
hyperkalemia in liver transplantation using donation 
Page 6 of 6 Translational Gastroenterology and Hepatology, 2019
© Translational Gastroenterology and Hepatology. All rights reserved. Transl Gastroenterol Hepatol 2019;4:68 | http://dx.doi.org/10.21037/tgh.2019.08.12
after cardiac death grafts with pathological changes. 
Hepatobiliary Pancreat Dis Int 2016;15:487-92.
11. Paugam-Burtz C, Kavafyan J, Merckx P, et al. 
Postreperfusion syndrome during liver transplantation 
for cirrhosis: outcome and predictors. Liver Transpl 
2009;15:522-9.
12. Kalisvaart M, de Haan JE, Hesselink DA, et al. The 
postreperfusion syndrome is associated with acute 
kidney injury following donation after brain death liver 
transplantation. Transpl Int 2017;30:660-9.
13. Leithead JA, Armstrong MJ, Corbett C, et al. Hepatic 
ischemia reperfusion injury is associated with acute 
kidney injury following donation after brain death liver 
transplantation. Transpl Int 2013;26:1116-25.
14. Zhang L, Tian M, Wei L, et al. Expanded Criteria Donor-
Related Hyperkalemia and Postreperfusion Cardiac 
Arrest During Liver Transplantation: A Case Report and 
Literature Review. Ann Transplant 2018;23:450-6.
15. Gumz ML, Rabinowitz L, Wingo CS. An Integrated 
View of Potassium Homeostasis. N Engl J Med 
2015;373:1787-8.
16. Huet PM, Nagaoka MR, Desbiens G, et al. Sinusoidal 
endothelial cell and hepatocyte death following cold 
ischemia-warm reperfusion of the rat liver. Hepatology 
2004;39:1110-9.
17. Angelico R, Perera MT, Ravikumar R, et al. 
Normothermic Machine Perfusion of Deceased Donor 
Liver Grafts Is Associated With Improved Postreperfusion 
Hemodynamics. Transplant Direct 2016;2:e97.
18. Nasralla D, Coussios CC, Mergental H, et al. A 
randomized trial of normothermic preservation in liver 
transplantation. Nature 2018;557:50-6.
19. Watson CJE, Kosmoliaptsis V, Randle LV, et al. 
Normothermic Perfusion in the Assessment and 
Preservation of Declined Livers Before Transplantation: 
Hyperoxia and Vasoplegia-Important Lessons From the 
First 12 Cases. Transplantation 2017;101:1084-98.
20. Patrono D, Lavezzo B, Molinaro L, et al. Hypothermic 
Oxygenated Machine Perfusion for Liver Transplantation: 
An Initial Experience. Exp Clin Transplant 2018;16:172-6.
21. Patrono D, Surra A, Catalano G, et al. Hypothermic 
Oxygenated Machine Perfusion of Liver Grafts from 
Brain-Dead Donors. Sci Rep 2019;9:9337.
22. Burlage LC, Hessels L, van Rijn R, et al. Opposite acute 
potassium and sodium shifts during transplantation 
of hypothermic machine perfused donor livers. Am J 
Transplant 2019;19:1061-71.
23. van Rijn R, Karimian N, Matton APM, et al. Dual 
hypothermic oxygenated machine perfusion in liver 
transplants donated after circulatory death. Br J Surg 
2017;104:907-17.
24. Kron P, Schlegel A, Mancina L, et al. Hypothermic 
oxygenated perfusion (HOPE) for fatty liver grafts in rats 
and humans. J Hepatol 2017. [Epub ahead of print].
25. Schlegel A, Muller X, Kalisvaart M, et al. Outcomes 
of DCD liver transplantation using organs treated by 
hypothermic oxygenated perfusion before implantation. J 
Hepatol 2019;70:50-7.
doi: 10.21037/tgh.2019.08.12
Cite this article as: Patrono D, Romagnoli R. Postreperfusion 
syndrome, hyperkalemia and machine perfusion in liver 
transplantation. Transl Gastroenterol Hepatol 2019;4:68.
